NASDAQ:IKT

Inhibikase Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy IKT

*Your capital is at risk

$1.87

+0.0300 (+1.63%)

At Close: Jun 23, 2026

Inhibikase Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 92.62. In total, the insiders bought 35.27M and sold 997.04K IKT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	92.62
● Buy	35.27M shares
● Sell	997.04K shares
81% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Jun 22, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 92.62. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (81% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 21, 2026 Sell	Common Stock D-Return	Munshi Amit Director	Director	19 089 Value: $0
Feb 21, 2026 Sell	Common Stock D-Return	Cabell Christopher President & Head Of R&d	CEO / President	338 282 Value: $0
Feb 21, 2026 Sell	Common Stock D-Return	Aurentz Vincent Director	Director	255 299 Value: $0
Jan 05, 2026 Buy	Stock Option (Right to Buy) A-Award	Mcintyre David Chief Financial Officer	C-Suite Officer	986 319 Value: $1.98M
Jan 05, 2026 Buy	Stock Option (Right to Buy) A-Award	Cabell Christopher President & Head Of R&d	CEO / President	900 117 Value: $1.81M
Jan 05, 2026 Buy	Stock Option (Right to Buy) A-Award	Iwicki Mark T Chief Executive Officer	CEO / President	4 982 706 Value: $10.0M
Nov 21, 2025 Buy	Common Stock P-Purchase	Sands Capital Life Sciences Pulse Fund Ii, L.p. 10 Percent Owner	10% Owner	2 068 965 Value: $3.00M
Jun 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Canner David Director	Director	108 176 Value: $210.9K
Jun 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Munshi Amit Director	Director	108 176 Value: $210.9K
Jun 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Kush Arvind Director	Director	108 176 Value: $210.9K
Jun 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Berman Dennis N Director	Director	108 176 Value: $210.9K
Jun 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Bellini Roberto Director	Director	108 176 Value: $210.9K
Jun 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Aurentz Vincent Director	Director	108 176 Value: $210.9K
Jun 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Bellini Roberto Director	Director	108 176 Value: $210.9K
Jun 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Berman Dennis N Director	Director	108 176 Value: $210.9K
Jun 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Kush Arvind Director	Director	108 176 Value: $210.9K
Jun 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Munshi Amit Director	Director	108 176 Value: $210.9K
Jun 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Canner David Director	Director	108 176 Value: $210.9K
Jun 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Aurentz Vincent Director	Director	108 176 Value: $210.9K
Jun 06, 2025 Buy	Common Stock	Sands Capital Life Sciences Pulse Fund Ii, L.p. 10 Percent Owner	10% Owner	0 Value: $0
Jun 06, 2025 Buy	Common Stock	Sands Capital Life Sciences Pulse Fund Ii, L.p. 10 Percent Owner	10% Owner	0 Value: $0
Apr 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Mcintyre David Chief Financial Officer	C-Suite Officer	1 775 539 Value: $3.55M
Apr 14, 2025 Buy	Common Stock	Mcintyre David Chief Financial Officer	C-Suite Officer	0 Value: $0
Apr 14, 2025 Buy	Common Stock	Mcintyre David Chief Financial Officer	C-Suite Officer	0 Value: $0
Apr 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Mcintyre David Chief Financial Officer	C-Suite Officer	1 775 539 Value: $3.55M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT INHIBIKASE THERAPEUTICS, INC.

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic const...

Read Full Profile Here